Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rocquain, Julien ^a   Carbuccia, Nadine ^a   Trouplin, Virginie ^a   Raynaud, Stéphane ^a   Murati, Anne ^a   Nezri, Meyer ^b   Tadrist, Zoulika ^c   Olschwang, Sylviane ^a   Vey, Norbert ^a,d   Birnbaum, Daniel ^a   Gelsi Boyer, Véronique ^a,d   Mozziconacci, Marie Joelle ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b Centre Hospitalier Genéral   (France)

^c Centre Hospitalier de Salon de Provence   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; ASXL1 GENE; CBL GENE; CONTROLLED STUDY; FEMALE; FLT3 GENE; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; HUMAN; IDH1 GENE; IDH2 GENE; JAK2 GENE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NPM1 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE K RAS; REFRACTORY ANEMIA WITH EXCESS BLASTS; RUNX1 GENE; TET2 GENE; WT1 GENE; AGED; GENETICS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS;

ASXL1 PROTEIN, HUMAN; CBL PROTEIN; CBL PROTEIN, HUMAN; CD135 ANTIGEN; DNA; DNA BINDING PROTEIN; FLT3 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; KRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOPHOSMIN; ONCOPROTEIN; RAS PROTEIN; REPRESSOR PROTEIN; RUNX1 PROTEIN, HUMAN; TET2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RUNX1; TUMOR PROTEIN; WT1 PROTEIN;

AGED; AGED, 80 AND OVER; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; RAS PROTEINS; REPRESSOR PROTEINS; WT1 PROTEINS;

EID: 77955081371     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-401     Document Type: Article

References (39)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Eng J Med 2009, 361:1872-1885.
2. Acquaviva C, Gelsi-Boyer V, Birnbaum D. Myelodysplastic syndromes: lost between two states?. Leukemia 2010, 24:1-5. 10.1038/leu.2009.157, 20068572.
3. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301. 10.1056/NEJMoa0810069, 19474426.
4. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009, 23:1343-1345. 10.1038/leu.2009.59, 19295549.
5. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009, 113:6403-6410. 10.1182/blood-2009-02-205690, 2710933, 19372255.
6. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao JJ, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147. 10.1182/blood-2009-03-210039, 2710942, 19420352.
7. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, Geurts van Kessel A, Raymakers RAP, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Janssen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842. 10.1038/ng.391, 19483684.
8. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, Strupp C, Gattermann N, Germing U, Mufti GJ. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndromes. J Clin Oncol 2009, 27:4002-4006. 10.1200/JCO.2009.22.6985, 19528370.
9. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDS). Blood 2009, 114:3285-3291. 10.1182/blood-2009-04-215814, 19666869.
10. Gelsi-Boyer V, Trouplin V, Adélaïde J, Bonansea J, Cervera N, Carbuccia N, Lagarde A, Prébet T, Nezri M, Sainty D, Olschwang S, Xerri L, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009, 145:788-800. 10.1111/j.1365-2141.2009.07697.x, 19388938.
11. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of E3 ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009, 27:6109-6116. 10.1200/JCO.2009.23.7503, 19901108.
12. Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, Nicoletti N. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia 2009, 23:1731-1743. 10.1038/leu.2009.124, 19516275.
13. Gaidzik V, Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal karyotype. Semin Oncol 2008, 35:346-355. 10.1053/j.seminoncol.2008.04.005, 18692685.
14. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Elred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ. Recurrent mutations found by sequencing an acute myeloid leukemia genome. N Eng J Med 2009, 361:1058-1066.
15. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélaïde J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010, 24:469-473. 10.1038/leu.2009.218, 19865112.
16. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002, 39:6-11. 10.1053/shem.2002.36921, 12447846.
17. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951. 10.1182/blood-2009-03-209262, 19357394.
18. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D. Genomic profiling of acute myelomonocytic leukemia: alteration of the MYB locusin MYST3-linked cases. Leukemia 2009, 23:85-94. 10.1038/leu.2008.257, 18818702.
19. Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008, 8:299-314. 10.1186/1471-2407-8-299, 2588460, 18925961.
20. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamasaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Nakazaki K, Kawamata N, Onodera M, Nobuyoshi M, Hayashi Y, Harada H, Kurokawa M, Chiba S, Mori H, Ozawa K, Omine M, Hirai H, Nakauchi H, Koeffler HP, Ogawa S. Gain-of-function of mutated CBL tumour suppressor in myeloid neoplasms. Nature 2009, 460:904-908. 10.1038/nature08240, 19620960.
21. Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O, Philippe N, Thomas X, Dombret H, Preudhomme C. Wilms tumor gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009, 115:3719-3727. 10.1002/cncr.24442, 19536888.
22. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, Allen C, Green C, Quentmeier H, Drexler H, Burnett A, Linch D, Bonnet D, Lister TA, Fitzgibbon J. Mutation of the Wilm's tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukaemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26:5429-5435. 10.1200/JCO.2008.16.0333, 18591546.
23. Green A, Beer P. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. New Engl J Med 2010, 362:369-370. 10.1056/NEJMc0910063, 20107228.
24. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett B, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su S, Sharp KA, Levine RL, Thompson CB. The common features of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydoxyglutarate. Cancer Cell 2010, 17:1-10. 10.1016/j.ccr.2010.01.020, 20129241.
25. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, Jädersten M, Killick S, Hellström-Lindbergh E, Cazzola M, Wainscoat JS. Frequent mutations of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062-1065. 10.1038/leu.2010.20, 20182461.
26. Lavagna-Sévenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998, 12:301-310. 10.1038/sj.leu.2400921, 9529123.
27. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H, Sekeres MA, Wang XF, McDevitt MA, Maciejewski JP. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008, 68:10340-10357.
28. Pollard PJ, Ratcliffe PJ. Puzzling patterns of predisposition. Science 2009, 324:192-194. 10.1126/science.1173362, 19359573.
29. Wagner KD, Wagner N, Wellman S, Schley G, Bondke A, Theres H, Scholz H. Oxygen-regulated expression of the Wilm's tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J 2003, 17:1364-1366.
30. Couronné L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, Penther D, et al. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 2010, 24:201-203. 10.1038/leu.2009.169, 19710701.
31. Bernard F, Gelsi-Boyer V, Murati A, Giraudier S, Trouplin V, Adélaïde J, Rey J, Olschwang S, Vainchenker W, Chaffanet M, Vey N, Mozziconacci MJ, Birnbaum D. Alterations of NFIA in chronic malignant myeloid diseases. Leukemia 2009, 23:583-585. 10.1038/leu.2008.228, 18754024.
32. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41:521-523. 10.1038/ng.349, 2873835, 19330029.
33. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NCP. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010,
34. Nikoloski G, Langemeijer SMC, Kuiper RP, Knops R, Massop M, Tönnissen ERLTM, van der Heijden A, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010,
35. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood 2009, 114:5201-5205. 10.1182/blood-2009-06-223982, 19850737.
36. Abdel-Wahab O, Mansouri T, Patel J, Harris K, Yao J, Hedvat C, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010, 70:447-452. 10.1158/0008-5472.CAN-09-3783, 20068184.
37. Dang L, White DW, Gross S, Bennett BD, Bittinger MAA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744. 10.1038/nature08617, 2818760, 19935646.
38. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006, 494:493-505.
39. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW. Loss-of-function Additional sex coombs-like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010, 115:38-46. 10.1182/blood-2009-07-230698, 19861679.